Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 2021

View Archived Issues

OTO-313 well tolerated and promising for treating tinnitus

Treatment with Escozine results in apoptosis of various types of leukemia cancer cell lines

Repare Therapeutics provides updates regarding its RP-6306 program

Context Therapeutics and Integral Molecular collaborate to develop novel anti-CLDN6 antibodies

Mersana initiates UPLIFT registration strategy for upifitamab rilsodotin

AACR 2021: Research points to ways to fight cachexia's bite

Pinteon Therapeutics initiates phase I study of PNT-001 in traumatic brain injury

Enrollment ongoing in phase I study of tomivosertib plus paclitaxel in advanced breast cancer

Takeda Pharmaceutical patents GPR139 agonists

Novartis AG discloses new PROTACs

Albert-Ludwigs-Universitat Freiburg synthesizes N6AMT1 inhibitors

BIAL - Biotech Investments presents new ASAH1 inhibitors

Moderna initiates phase I study of its COVID-19 variant vaccine mRNA-1273.351

Genentech and Roche discover new KLK7-targeting antibodies

Phase III study of casirivimab + imdevimab to prevent symptomatic COVID-19 infection meets endpoints

Pooled data from the AURORA and AURA-LV trials across lupus nephritis biopsy classes

Antengene initiates phase II study of ATG-008 in advanced solid tumors with genetic alterations

SEMA7A is a prognostic factor in ER+ breast cancer

Data from ongoing phase Ib/II study of onvansertib in second-line metastatic colorectal cancer

New phase III study assesses contraceptive efficacy of relugolix combination tablet

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...